Actual status of antiinterleukin-1 therapies in rheumatic diseases

Current Opinion in Rheumatology

Volumn 22, Issue 3, 2010, Pages 246-251

  Geyer, Matthias ^a   Müller Ladner, Ulf ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Arthritis; Autoinflammatory syndromes; Gout; Inflammation; Interleukin 1b; Joint destruction

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; COLLAGENASE 3; CYCLOSPORIN A; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEFLUNOMIDE; LEUKEMIA INHIBITORY FACTOR; LLARIS; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SALAZOSULFAPYRIDINE; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GASTRITIS; GOUT; HUMAN; INFECTION; INJECTION SITE REACTION; JOINT DESTRUCTION; JUVENILE RHEUMATOID ARTHRITIS; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1; RECOMBINANT FUSION PROTEINS; RHEUMATIC DISEASES;

EID: 77950258225     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283373fa0     Document Type: Review

References (30)

1. March CJ, Mosley B, Larsen A, etal. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985; 315:641-647.
2. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 1994; 8:1 314-1325.
3. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343:341-346.
4. Carter DB, Deibel MR Jr, Dunn CJ, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990; 344:633-638.
5. Sims JE, Gayle MA, Slack JL, etal. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci USA 1993; 90:6155-6159.
6. Colotta F, Re F, Muzio M, etal. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993; 261:472-475.
7. Kurt-Jones EA, Beller DI, Mizel SB, et al. Identification of a membrane-associated interleukin 1 in macrophages. Proc Natl Acad Sci USA 1985; 82:1204-1208.
8. Weitzmann MN, Savage N. Nuclear internalisation and DNA binding activities of interleukin-1, interleukin-1 receptor and interleukin-1/receptor complexes. Biochem Biophys Res Commun 1992; 187:1166-1171.
9. Black RA, Kronheim SR, Sleath PR. Activation of interleukin-1 beta by a co-induced protease. FEBS Lett 1989; 247:386-390.
10. Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol 2005; 26:447-454.
11. Kanneganti TD, Ozoren N, Body-Malapel M, et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006; 440:233-236.
12. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-241.
13. Mariathasan S, Weiss DS, Newton K, etal. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440:228-232.
14. Petrilli V, Papin S, Dostert C, et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007; 14:1583-1589.
15. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201:1355-1359.
16. Sandell LJ,Xing X, Franz C, etal. Exuberant expression of chemokine genes by adult human articular chondrocytes in response to IL-1beta. Osteoarthritis Cartilage 2008; 16:1560-1571.
17. OttavianiS,Tahiri K, FrazierA, etal. HES1, a new target for interleukin-1beta in chondrocytes. Ann Rheum Dis [Epub ahead of print].
18. Zwerina J, Redlich K, Polzer K, et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007; 104:11742-11747.
19. Kolly L, Busso N, Palmer G, et al. Expression and function of the NALP3 inflammasome in rheumatoid synovium. Immunology [Epub ahead of print]. Chen CJ, Shi Y, Hearn A, etal. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006; 116:2262-2271.
20. Church LD, Savic S, McDermott MF. Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 trap). Biologics 2008; 2:733-742.
21. Ikonomidis I, Lekakis JP, Nikolaou M, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008; 117:2662-2669.
22. Karanikolas G, Charalambopoulos D, VaiopoulosG, et al. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or lefluno-mide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study. Rheumatology 2008; 47:1384-1388.
23. Le Loet X, Nordstrom D, Rodriguez M, et al. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA trial. J Rheumatol 2008; 35:1538-1544.
24. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009; 36:1118-1125.
25. Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009; 28:129-137.
26. Zeft A, Hollister R, LaFleur B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 2009; 15:161-164.
27. Ruperto N, Quartier P, Wulffraat N, et al. A phase II trial with canakinumab, a new IL-1 beta blocking monoclonal antibody (ACZ885), to evaluate prelimin ary dosing, safety and efficacy profile in children with systemic juvenile idiopathic arthritis (sJIA). Pediatr Rheumatol 2008; 6:S2.
28. Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (inter leukin-1 trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008; 58:2432-2442.
29. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58:2443-2452.
30. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomised, single-blind pilot study. Ann Rheum Dis 2009; 68:1613-1617.